Article Sidebar
Views PDF: 5
Early evaluation of results using DynamX bioadaptor coated with Novolimus in the treatment of coronary artery disease at E Hospital
Main Article Content
Abstract
Objective: To evaluate the early outcomes of using DynamX bioadaptor coated with novolimus in the treatment of coronary artery disease. Methods: Prospective, descriptive study without a control group. Results: 70 patients were enrolled in the study. The mean age was 70.4±7,9 years. Males accounted for 61.4%. Most were hospitalized with a diagnosis of acute coronary syndrome (89%). The most common lesion was the left anterior descending artery (47.1%) with a calcification and tortuosity rate of 14.2% and 7.1%, respectively. The clinical success rate was 98.6%. No major complications were reported during the procedure. There was a significant improvement in chest pain, shortness of breath, and cardiac function at 1 and 3 months follow-up. No major cardiovascular events were reported at 1 and 3 months follow-up. Conclusion: The study demonstrated the safety of DynamX bioadaptor coated with novolimus in the early treatment of coronary artery disease.
Article Details
Keywords
Bioadaptor, DynamX, Novolimus, Coronary artery disease, Dynam X, Novolimus, Coronary artery disease, Bioadaptor
References
2. Schmidt W, Lanzer P, Behrens P, Brandt-Wunderlich C, Öner A, Ince H, et al. Direct comparison of coronary bare metal vs. drug-eluting stents: Same platform, different mechanics? Eur J Med Res. 2018 Jan 8; 23:2.
3. Verheye S, Vrolix M, Montorfano M, Giannini F, Bedogni F, Dubois C, et al. Final 36-month outcomes from the multicenter Dynam X study evaluating a novel thin-strut novolimus-eluting coronary bioadaptor system and supporting preclinical data. Rev Cardiovasc Med. 2023 Aug; 24(8):221.
4. Saito S, Nef HM, Webster M, Verheye S. Dynam X sirolimus-eluting Bioadaptor versus the zotarolimus-eluting Resolute Onyx stent in patients with de novo coronary artery lesions: Design and rationale of the multi-center, international, randomized BIOADAPTOR-RCT. Cardiovasc Revasc Med. 2023 Oct 1; 55:76-82.
5. Erlinge D, Andersson J, Fröbert O, Törnerud M, Böhm F, Held C, et al. Rationale and design of INFINITY-SWEDEHEART: A registry-based randomized clinical trial comparing clinical outcomes of the sirolimus-eluting Dynam X bioadaptor to the zotarolimus-eluting Resolute Onyx stent. Am Heart J. 2024 Nov; 277:1-10.
6. Saito S, Nef HM, Webster M, Verheye S. Dynam X sirolimus-eluting Bioadaptor versus the zotarolimus-eluting Resolute Onyx stent in patients with de novo coronary artery lesions: Design and rationale of the multi-center, international, randomized BIOADAPTOR-RCT. Cardiovasc Revasc Med. 2023 Oct; 55:76-82.